Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase 3 1Phase 1/2 1

Status

Completed 2Unknown 1Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Breast 1

Conditions

Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Completed × Drug Evaluation × Clear all
NCT04500587 2024-09-19

Phase 1 First in Human Study of ZN-d5 as a Single Agent

K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Phase 1 Completed
39 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Myeloid, Acute

NCT03236974 2020-02-06

D6090C00002

AstraZeneca

Phase 1 Completed
49 enrolled
Breast

Postmenopausal Women With ER+ HER2- Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡